Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis.
about
Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia.Pharmacogenetics and Pharmacogenomics of Targeted Therapeutics in Chronic Myeloid Leukemia.The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia.
P2860
Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Trough concentration and ABCG2 ...... oid leukemia: a meta-analysis.
@en
Trough concentration and ABCG2 ...... oid leukemia: a meta-analysis.
@nl
type
label
Trough concentration and ABCG2 ...... oid leukemia: a meta-analysis.
@en
Trough concentration and ABCG2 ...... oid leukemia: a meta-analysis.
@nl
prefLabel
Trough concentration and ABCG2 ...... oid leukemia: a meta-analysis.
@en
Trough concentration and ABCG2 ...... oid leukemia: a meta-analysis.
@nl
P2093
P2860
P356
P1433
P1476
Trough concentration and ABCG2 ...... oid leukemia: a meta-analysis.
@en
P2093
Biswajit Dubashi
Naoto Takahashi
Sabrina Angelini
Xie-Lan Zhao
Zhi-Ping Jiang
P2860
P356
10.2217/PGS-2016-0103
P577
2016-12-19T00:00:00Z